Picture loading failed.

Pre-Made Firivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-214-1mg 1mg 3090
GMP-Bios-ab-214-10mg 10mg Inquiry
GMP-Bios-ab-214-100mg 100mg Inquiry
GMP-Bios-ab-214-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Firivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody
INN Name Firivumab
TargetInfluenza A HA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preclinical
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesCelltrion
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedInfluenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections
Development Techna